Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could testosterone boost kidney transplant success?

NCT ID NCT07287800

Disease control Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving testosterone to men with low testosterone and kidney failure can help them recover better after a kidney transplant. About 50 men will receive testosterone before and after their transplant, and their safety and recovery will be compared to a similar group from the past. The goal is to see if this approach reduces complications and improves graft survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Testosterone Replacement Therapy
What this could lead to
If it works, this could improve recovery and quality of life for men with low testosterone undergoing kidney transplantation.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply to everyone. Testosterone therapy also carries risks like heart problems or prostate issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients older than 18 years old with confirmed end-stage renal disease (ESRD). * Hypogonadal (testosterone level \<300 ng/dL) with clinical symptoms of hypogonadism. * Expected to undergo kidney transplantation within a 6-month period. * Able and willing to comply with study procedures and follow-up visits. Exclusion Criteria: * Women or non-hypogonadal men. * Any contraindications to testosterone therapy, including: * History of Breast Cancer * Severe untreated OSA * Polycythemia (Hct \>54%) * Uncontrolled chronic heart failure (CHF) * A history of a Major Adverse Cardiac Event (MACE) within the past 6 months * Interest in fertility within 1 year * An unevaluated PSA \>4.0 ng/mL or a PSA \>3.0 ng/mL in individuals with risk factors for prostate cancer defined as: * Men with African ancestry * Men with first-degree relative with prostate cancer * Known genetic mutations including BRCA1/2 * A history of Lynch Syndrome * Abnormal DRE * Participants already receiving testosterone or other androgen therapies. * Severe cardiovascular or pulmonary conditions that pose a high surgical risk. * Any condition that, in the opinion of the investigator, would make the subject ineligible for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease (ESRD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure eunuchism hypogonadism, male

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage renal disease (ESRD) Hypogonadism, male Kidney transplant

Contacts and locations

Locations

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.